NeuroMetrix, Inc. (NASDAQ:NURO) Sees Significant Decrease in Short Interest

NeuroMetrix, Inc. (NASDAQ:NURO) was the recipient of a large decrease in short interest in February. As of February 15th, there was short interest totalling 1,400 shares, a decrease of 48.1% from the January 31st total of 2,700 shares. Based on an average daily volume of 20,600 shares, the short-interest ratio is presently 0.1 days. Approximately 0.1% of the company’s stock are short sold.

NeuroMetrix Trading Down 0.2 %

Shares of NASDAQ NURO opened at $4.38 on Friday. NeuroMetrix has a 12-month low of $2.66 and a 12-month high of $4.73. The company has a market cap of $8.99 million, a P/E ratio of -0.95 and a beta of 2.18. The stock has a fifty day moving average price of $4.17 and a 200 day moving average price of $4.03.

Institutional Trading of NeuroMetrix

An institutional investor recently bought a new position in NeuroMetrix stock. GTS Securities LLC bought a new stake in shares of NeuroMetrix, Inc. (NASDAQ:NURO) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 22,759 shares of the medical device company’s stock, valued at approximately $90,000. GTS Securities LLC owned approximately 1.12% of NeuroMetrix at the end of the most recent reporting period. Institutional investors own 19.40% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, StockNews.com assumed coverage on NeuroMetrix in a report on Monday, February 24th. They issued a “sell” rating for the company.

NeuroMetrix Company Profile

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.